LT3645002T - Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais - Google Patents
Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriaisInfo
- Publication number
- LT3645002T LT3645002T LTEPPCT/US2018/040181T LTUS2018040181T LT3645002T LT 3645002 T LT3645002 T LT 3645002T LT US2018040181 T LTUS2018040181 T LT US2018040181T LT 3645002 T LT3645002 T LT 3645002T
- Authority
- LT
- Lithuania
- Prior art keywords
- sarcomer
- activators
- cardiac
- heart failure
- treating heart
- Prior art date
Links
- 206010019280 Heart failures Diseases 0.000 title 1
- 239000012190 activator Substances 0.000 title 1
- 230000000747 cardiac effect Effects 0.000 title 1
- 210000002235 sarcomere Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762527983P | 2017-06-30 | 2017-06-30 | |
| PCT/US2018/040181 WO2019006235A1 (en) | 2017-06-30 | 2018-06-29 | METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3645002T true LT3645002T (lt) | 2025-02-10 |
Family
ID=63013097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/US2018/040181T LT3645002T (lt) | 2017-06-30 | 2018-06-29 | Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US11576910B2 (enExample) |
| EP (2) | EP3645002B1 (enExample) |
| JP (3) | JP2020526483A (enExample) |
| CN (1) | CN110996953A (enExample) |
| AU (2) | AU2018290983B2 (enExample) |
| BR (1) | BR112019028046A2 (enExample) |
| CA (1) | CA3068588A1 (enExample) |
| DK (1) | DK3645002T3 (enExample) |
| ES (1) | ES3008457T3 (enExample) |
| FI (1) | FI3645002T3 (enExample) |
| HR (1) | HRP20241729T1 (enExample) |
| HU (1) | HUE069805T2 (enExample) |
| LT (1) | LT3645002T (enExample) |
| MA (1) | MA49508B1 (enExample) |
| MD (1) | MD3645002T2 (enExample) |
| MX (2) | MX2020000190A (enExample) |
| PL (1) | PL3645002T3 (enExample) |
| PT (1) | PT3645002T (enExample) |
| RS (1) | RS66581B1 (enExample) |
| SI (1) | SI3645002T1 (enExample) |
| SM (1) | SMT202500067T1 (enExample) |
| WO (1) | WO2019006235A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014240049C1 (en) | 2013-03-14 | 2019-03-07 | Amgen Inc. | Heterocyclic compounds and their uses |
| IL270663B (en) | 2017-06-30 | 2022-08-01 | Amgen Inc | Synthesis of omecamtib from carbyl |
| AU2018290983B2 (en) | 2017-06-30 | 2023-11-23 | Amgen Inc. | Methods of treating heart failure with cardiac sarcomere activators |
| ES2815899T3 (es) | 2018-07-09 | 2021-03-31 | Fis Fabbrica Italiana Sintetici Spa | 2-Fluoro-3-nitrotolueno cristalino y procedimiento para la preparación del mismo |
| MX2021001792A (es) | 2018-08-17 | 2021-05-27 | Amgen Inc | Sales y formas cristalinas de omecamtiv mecarbil. |
| SG11202112723PA (en) * | 2019-05-19 | 2021-12-30 | Myokardia Inc | Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide |
| IL295490A (en) * | 2020-02-10 | 2022-10-01 | Amgen Inc | omecamtiv mecarbil tablet |
| CA3180943A1 (en) * | 2020-06-15 | 2021-12-23 | Jean-Francois TAMBY | Treatment of atrial dysfunction |
| CN116710139A (zh) * | 2020-11-12 | 2023-09-05 | 安进股份有限公司 | 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法 |
| WO2022103966A1 (en) | 2020-11-12 | 2022-05-19 | Amgen Inc. | Methods of treating heart failure by administering omecamtiv mecarbil |
| AU2022232919A1 (en) | 2021-03-10 | 2023-10-19 | Amgen Inc. | Synthesis of omecamtiv mecarbil |
| US20250161298A1 (en) * | 2022-02-22 | 2025-05-22 | Yale University | Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth |
| WO2024081611A1 (en) * | 2022-10-11 | 2024-04-18 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
| AU2024248193A1 (en) | 2023-03-27 | 2025-10-09 | Edgewise Therapeutics, Inc. | Quinolinone amide compounds and uses thereof |
| US11986474B1 (en) | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
| KR20010040819A (ko) | 1998-02-10 | 2001-05-15 | 가마꾸라 아끼오 | 제어방출형 제제 |
| GB2344287A (en) | 1998-12-03 | 2000-06-07 | Ferring Bv | Controlled release pharmaceutical formulation |
| WO2004033036A2 (en) | 2002-10-04 | 2004-04-22 | Microchips, Inc. | Medical device for controlled drug delivery and cardiac monitoring and/or stimulation |
| NZ552404A (en) | 2004-06-17 | 2010-04-30 | Cytokinetics Inc | Compounds, compositions and methods |
| EP1959960B1 (en) | 2005-12-15 | 2013-04-10 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
| WO2007133747A2 (en) | 2006-05-15 | 2007-11-22 | Wisconsin Alumni Research Foundation | PULMONARY DELIVERY OF 1α,25-DIHYDROXYVITAMIN D3 AND CO-ADMINISTRATION OF PARATHYROID HORMONE OR CALCITONIN |
| FR2902092B1 (fr) | 2006-06-07 | 2008-09-05 | Sapelem Soc Par Actions Simpli | Appareil de manutention de charge |
| RU2422134C1 (ru) | 2007-04-19 | 2011-06-27 | Донг-А Фармасьютикал. Ко., Лтд | Композиция биоразлагающихся микросфер, пригодная для контролируемого высвобождения контролирующего уровень глюкозы пептида, и ее состав |
| AU2014240049C1 (en) | 2013-03-14 | 2019-03-07 | Amgen Inc. | Heterocyclic compounds and their uses |
| ES2733340T3 (es) * | 2013-03-14 | 2019-11-28 | Amgen Inc | Compuestos heterocíclicos y sus usos |
| WO2016123291A1 (en) | 2015-01-29 | 2016-08-04 | Signal Pharmaceuticals, Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| WO2016210240A1 (en) * | 2015-06-26 | 2016-12-29 | Amgen Inc. | Combination therapy of cardiac myosin activator and sinus node if current inhibitor |
| CN110603049A (zh) | 2017-02-06 | 2019-12-20 | 阿塞勒隆制药公司 | 用于治疗心力衰竭的组合物和方法 |
| IL270663B (en) | 2017-06-30 | 2022-08-01 | Amgen Inc | Synthesis of omecamtib from carbyl |
| AU2018290983B2 (en) | 2017-06-30 | 2023-11-23 | Amgen Inc. | Methods of treating heart failure with cardiac sarcomere activators |
| ES2815899T3 (es) | 2018-07-09 | 2021-03-31 | Fis Fabbrica Italiana Sintetici Spa | 2-Fluoro-3-nitrotolueno cristalino y procedimiento para la preparación del mismo |
| WO2020014406A1 (en) | 2018-07-12 | 2020-01-16 | Assia Chemical Industries Ltd. | Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl |
| DK3599243T3 (da) | 2018-07-26 | 2023-07-10 | Cvie Therapeutics Ltd | 17beta-heterocyklyl-digitalis-lignende forbindelser til behandlingen af hjertesvigt |
| MX2021001792A (es) | 2018-08-17 | 2021-05-27 | Amgen Inc | Sales y formas cristalinas de omecamtiv mecarbil. |
| WO2020131574A1 (en) | 2018-12-18 | 2020-06-25 | Amgen Inc. | Method of reducing aromatic nitro compounds |
| EP3934654A1 (en) | 2019-03-05 | 2022-01-12 | Windtree Therapeutics, Inc. | Istaroxime-containing intravenous formulation for the treatment of acute heart failure (ahf) |
| US20220340542A1 (en) | 2019-09-19 | 2022-10-27 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| US20220348543A1 (en) | 2019-09-19 | 2022-11-03 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| US20220402874A1 (en) | 2019-10-09 | 2022-12-22 | Dr. Reddy's Laboratories Limited | Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof |
| WO2021070124A1 (en) | 2019-10-09 | 2021-04-15 | Dr. Reddy’S Laboratories Limited | Alternate processes for the preparation of omecamtiv mecarbil |
| BR112022008641A2 (pt) | 2019-11-10 | 2022-09-13 | Myokardia Inc | Métodos de tratamento com modulador de miosina |
| GB201918853D0 (en) | 2019-12-19 | 2020-02-05 | Lund Lars H | Methods of treatment |
| CN114929671B (zh) | 2020-01-03 | 2024-04-16 | 苏州科睿思制药有限公司 | 化合物i二盐酸盐的共晶及其制备方法和用途 |
| IL295490A (en) | 2020-02-10 | 2022-10-01 | Amgen Inc | omecamtiv mecarbil tablet |
| WO2022103966A1 (en) | 2020-11-12 | 2022-05-19 | Amgen Inc. | Methods of treating heart failure by administering omecamtiv mecarbil |
| AU2022232919A1 (en) | 2021-03-10 | 2023-10-19 | Amgen Inc. | Synthesis of omecamtiv mecarbil |
| WO2023205291A2 (en) | 2022-04-21 | 2023-10-26 | The Board Of Regents Of The University Of Oklahoma | Targeting myocardial tissue for delivery of therapeutic and imaging agents |
| WO2024081611A1 (en) | 2022-10-11 | 2024-04-18 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
| US11986474B1 (en) * | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
-
2018
- 2018-06-29 AU AU2018290983A patent/AU2018290983B2/en active Active
- 2018-06-29 WO PCT/US2018/040181 patent/WO2019006235A1/en not_active Ceased
- 2018-06-29 SI SI201831198T patent/SI3645002T1/sl unknown
- 2018-06-29 PL PL18745732.0T patent/PL3645002T3/pl unknown
- 2018-06-29 MD MDE20200488T patent/MD3645002T2/ro unknown
- 2018-06-29 HU HUE18745732A patent/HUE069805T2/hu unknown
- 2018-06-29 DK DK18745732.0T patent/DK3645002T3/da active
- 2018-06-29 US US16/625,958 patent/US11576910B2/en active Active
- 2018-06-29 MA MA49508A patent/MA49508B1/fr unknown
- 2018-06-29 MX MX2020000190A patent/MX2020000190A/es unknown
- 2018-06-29 BR BR112019028046-4A patent/BR112019028046A2/pt not_active Application Discontinuation
- 2018-06-29 EP EP18745732.0A patent/EP3645002B1/en active Active
- 2018-06-29 ES ES18745732T patent/ES3008457T3/es active Active
- 2018-06-29 RS RS20250023A patent/RS66581B1/sr unknown
- 2018-06-29 PT PT187457320T patent/PT3645002T/pt unknown
- 2018-06-29 EP EP24209435.7A patent/EP4512470A3/en active Pending
- 2018-06-29 CN CN201880053343.0A patent/CN110996953A/zh active Pending
- 2018-06-29 HR HRP20241729TT patent/HRP20241729T1/hr unknown
- 2018-06-29 LT LTEPPCT/US2018/040181T patent/LT3645002T/lt unknown
- 2018-06-29 CA CA3068588A patent/CA3068588A1/en active Pending
- 2018-06-29 FI FIEP18745732.0T patent/FI3645002T3/fi active
- 2018-06-29 SM SM20250067T patent/SMT202500067T1/it unknown
- 2018-06-29 JP JP2019570045A patent/JP2020526483A/ja active Pending
-
2020
- 2020-01-08 MX MX2022015115A patent/MX2022015115A/es unknown
-
2023
- 2023-01-17 US US18/155,483 patent/US12295952B2/en active Active
- 2023-03-15 JP JP2023040600A patent/JP2023088944A/ja active Pending
- 2023-05-05 US US18/313,267 patent/US11931358B2/en active Active
-
2024
- 2024-02-15 AU AU2024200991A patent/AU2024200991B2/en active Active
-
2025
- 2025-04-18 US US19/183,619 patent/US20250255862A1/en active Pending
- 2025-07-18 JP JP2025121073A patent/JP2025165979A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3645002T (lt) | Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais | |
| IL253954A0 (en) | Implantable devices and related methods for heart failure monitoring | |
| IL271059A (en) | Determination of cardiac parameters for modulation of blood pump support | |
| IL272300A (en) | Mavacamten for use in the treatment of hypertrophic cardiomyopathy | |
| EP3157468C0 (en) | SURGICAL HEART VALVES IDENTIFIABLE AFTER IMPLANTATION | |
| EP4230133C0 (en) | CONTROLLED AND PRECISE TREATMENT OF CARDIAC TISSUES | |
| EP3875139C0 (en) | TREATMENT OF VENOUS DISEASES | |
| IL253351A0 (en) | Cardiac stimulation of conduction pathways between the atria and ventricles and of tissues associated with these pathways | |
| EP3520560A4 (en) | Pdcch monitoring after drx configuration or reconfiguration | |
| IL247088B (en) | Matching and tracking time sequences of heart activation | |
| EP3298235A4 (en) | PREDICTION OF FORMATION AND STRATIGRAPHIC LAYERS DURING DRILLING | |
| EP3724219A4 (en) | TREATMENT OF FIBROSIS BY GENETICALLY MODIFIED MACROPHAGES | |
| LT3359037T (lt) | Informacios apie širdies būklę gavimo būdas ir aparatas | |
| HUE041700T2 (hu) | Hosszú, nem kódoló RNS-ek (IncRNS-ek) szívhipertrófia terápiájára és diagnosztizálására | |
| LT3728410T (lt) | Lignoceliuliozės biomasės apdorojimo būdas | |
| BR112018005499A2 (pt) | métodos de tratamento de pressão intraocular com ativadores de tie-2. | |
| DK4212152T3 (da) | Sacubitril-valsartan-doseringsregime til behandling af kronisk systolisk hjertesvigt | |
| EP3424557A4 (en) | INTRAKARDIAL DEFIBRILLATION CATHETER | |
| ZA202002292B (en) | Methods of treating heart failure with preserved ejection fraction | |
| EP3436569A4 (en) | ADVANCED DIRECT CARDIAL PROGRAMMING | |
| EP3923963A4 (en) | TREATMENT OF HEART FAILURE | |
| EP3256137A4 (en) | Method of treating heart failure | |
| EP3210575C0 (en) | CARDIAC IMPLANT | |
| HUE063820T2 (hu) | Módszerek kardiovaszkuláris betegségek kezelésére | |
| EP3223903C0 (en) | CARDIAC PACING DETECTION AND REGULATION |